Canidryl 50 mg Tablets for Dogs

Nchi: Uingereza

Lugha: Kiingereza

Chanzo: VMD (Veterinary Medicines Directorate)

Viambatanisho vya kazi:

Carprofen

Inapatikana kutoka:

Chanelle Pharmaceuticals Manufacturing Ltd

ATC kanuni:

QM01AE91

INN (Jina la Kimataifa):

Carprofen

Dawa fomu:

Tablet

Dawa ya aina:

POM-V - Prescription Only Medicine – Veterinarian

Kundi la matibabu:

Dogs

Eneo la matibabu:

Anti Inflammatory NSAID

Idhini hali ya:

Authorized

Idhini ya tarehe:

2006-12-12

Tabia za bidhaa

Revised: September 2011
AN: 01173/2010
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Canidryl 50 mg Tablets for dogs.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE INGREDIENT
Carprofen
50.0 mg/tablet
EXCIPIENTS
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablet
A plain round flat bevelled edge white to off white tablet with a
breakline on
one side. The tablets can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of inflammation and pain caused by musculo-skeletal
disorders and
degenerative joint disease. As a follow up to parenteral analgesia in
the
management of post-operative pain following soft tissue surgery.
4.3
CONTRA-INDICATIONS
Do not use in cats.
Do not use in case of hypersensitivity to active substance or to any
of the
excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there
is a possibility of gastro-intestinal ulceration or bleeding, or where
there is
evidence of a blood dyscrasia.
Refer to section 4.7.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to Sections 4.3 and 4.5
Revised: September 2011
AN: 01173/2010
Page 2 of 6
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
Use in dogs less than 6 weeks of age, or in aged dogs, may involve
additional risk.
If such a use cannot be avoided, dogs may require careful clinical
management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is
a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment
of
inflammatory conditions associated with bacterial infection,
appropriate
concurrent antimicrobial therapy should be instigated.
Do not administer other NSAIDs concurrently or within 24 hours of each
other. Some NSAIDs may be highly bound to plasma proteins and
compete with othe